Registered Members of Investor Village: Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password.
MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.
For assistance call 888-222-7309 or email email@example.com
[REDACTED] is exercised and assuming an [REDACTED] of HK$[REDACTED] per [REDACTED], being the mid-point of the indicative [REDACTED] range of HK$[REDACTED] to HK$[REDACTED] per [REDACTED] in this documents. We intend to use the net [REDACTED] we will receive from the [REDACTED] for the following purposes, subject to changes in light of our evolving business needs and changing market conditions:
Š approximately [REDACTED]% of net [REDACTED], or approximately HK$[REDACTED], for improving our capital structure and repaying existing debt, including our loan facility of RMB588 million at China Merchants Bank for the acquisition of Topknow, US$30.7 million at Ping An Bank of China and US$42.5 million at Bank of China due in June 2020, February 2021 and July 2020 respectively, and interest rate of 4.785%, 3 month libor+1.5% and 3 month libor+1.3%, respectively. For more details, see “Financial Information—Indebtedness”.
Š approximately [REDACTED]% of net [REDACTED], or approximately HK$[REDACTED], for our expansion of the sales and marketing network and infrastructure in the EU and other global markets.
Š approximately [REDACTED]% of net [REDACTED], or approximately HK$[REDACTED], for expanding our development and manufacturing capacity and broadening our product and services offering of Cytovance.
Š approximately [REDACTED]% of net [REDACTED], or approximately HK$[REDACTED], for investment in innovative drugs.